Efficacy and Safety of Conventional Immunosuppressant Therapies in Elderly Patients With Neuromyelitis Optica Spectrum Disorder
NCT ID: NCT07032337
Last Updated: 2025-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2985 participants
OBSERVATIONAL
2011-01-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inectolizumab With Steroid Optimization in Newly Treated NMOSD
NCT07159893
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT06180278
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders
NCT03350633
Autologous Transplant To End NMO Spectrum Disorder
NCT03829566
Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder
NCT06673394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IST group
patients who initiated any ISTs
No interventions assigned to this group
non-IST group
patients who did not initiate any ISTs
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients had used ISTs (excluding steroids) prior to the NMOSD diagnosis.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samsung Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ju-Hong Min
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IST_NMOSD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.